In today's world, Ro4938581 has become a topic of great relevance and interest among a wide public. From its origins to its impact on contemporary society, Ro4938581 has captured the attention of academics, professionals and enthusiasts alike. With a rich and complex history, Ro4938581 has evolved over the years, influencing different aspects of everyday life and playing a crucial role in numerous areas. In this article, we will thoroughly explore the importance of Ro4938581 and its influence in various fields, from culture to economics, politics and technology.
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C13H8BrF2N5 |
Molar mass | 352.143 g·mol−1 |
3D model (JSmol) | |
| |
|
Ro4938581 is a nootropic drug invented in 2009 by a team working for Hoffmann-La Roche, which acts as a subtype-selective inverse agonist at the α5 subtype of the benzodiazepine binding site on the GABAA receptor. It has good selectivity for the α5 subtype and did not produce convulsant or anxiogenic effects in animal studies, making it a promising potential nootropic. Ro4938581 and a related derivative basmisanil (RG-1662, RO5186582) have subsequently been investigated for the alleviation of cognitive dysfunction in Down syndrome.